Utah Medical Products Inc (Nasdaq: UTMD), a maker of specialty medical devices for hospitals, is offering to buy back up to 650,000 shares, about 20% of the company, at $75.00 each in a tender that now expires October 27, 2026. Rod Alzmann (@RodAlzmann), a special-situations investor on X, flagged the deal early and noted on October 12, 2026 that the stock briefly traded above the $75 offer. The open questions are what the stock is worth after a fifth of the shares are retired and whether shrinking sales justify the CEO's claim that $75 is still cheap.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Utah Medical Products Inc, UTMD, Nasdaq.
- Situation type: Fixed-price issuer tender offer with odd-lot priority.
- The offer: Up to 650,000 shares at $75.00 cash, about 20.4% of the 3,182,818 shares outstanding on June 30, 2026, with no minimum condition.
- Timing: The offer began September 24, 2026 and was extended from October 7 to 5:00 p.m. New York time on October 27, 2026. Third-quarter results are due October 22, 2026.
- Odd-lot rule: Holders of fewer than 100 shares as of the close of business on September 22, 2026 who tender all of them avoid proration.
- Price: UTMD closed at $74.41 on October 12, 2026, versus $70.67 on September 14, 2026, before the plan was public.
- Main risk: Sales are falling, and the stock could trade lower once the company stops buying.
Is UTMD a good bet right now?
The tender sets a near-term reference price of $75, but it does not settle long-term value. Shares tendered above the 650,000 cap from holders who do not qualify for odd-lot priority will be prorated, and any shares not accepted go back to their owners at whatever the market pays after October 27.
Utah Medical is funding the offer, up to about $48.75 million, from cash. It reported $87.5 million of cash and investments and no debt on June 30, 2026.
Why the tender has investors' attention
- Management says $75 is too low. CEO Kevin Cornwell wrote in the offer announcement, "I would like to be clear that in my opinion UTMD's shares are presently undervalued, even at $75.00 per share." He put fair value in the $90 per share range using industry multiples.
- The premium. The company said $75 was a 17% premium to the 12-month average closing price and 21% to the 24-month average.
- Fewer shares. Retiring a fifth of the shares would spread trailing EBITDA of about $15.7 million over a much smaller base.
- Small-holder mechanics. Odd-lot priority guarantees full acceptance for qualifying holders of fewer than 100 shares.
Who's making this call and why?
Rod Alzmann (@RodAlzmann) describes himself as a private investor focused on special situations and has about 23,800 followers on X. He often posts tender and exchange-offer math.
On September 16, 2026 he wrote, "$UTMD will be launching a $75/sh fixed price tender for 20% of shares with odd lot priority on the 22nd." He estimated the gap to the offer at about $1 a share at the time. On October 12, 2026 he added, "Spot price exceeded the odd lot tender fixed $75--allowing nimble shareholders to sell to Mr. Market this morning at prices in excess of the delayed tender payment's present value." His point: a sale in the market at $75 or more pays now, while the tender pays only after it closes.
Track record. In our tracking, Rod Alzmann is 5-5 (a .500 win rate) on 10 calls scored at 180 days against the S&P 500, with an average edge of -19.0 percentage points, and he is unranked because he has fewer than 15 scored calls. His UTMD posts are logged as neutral and not scored. See the scoreboard.
Other supporters:
- Special Situations Digest (@specsitsdigest), a weekly digest by Clark Square Capital, wrote, "Small odd-lot opportunity in $UTMD -- you can make $80 (99 shares * $0.80)"
- Inelegant Investor (@inelegantinvest) called it "Great mechanics." while noting the gross spread on 99 shares was only about $37.
Who disagrees?
- Kip Johann-Berkel (@BerkelKip) pointed out that the odd-lot record date of September 22 came before the offer formally began, writing, "No buying 99 shares for beer money". Shares bought after that date do not get priority.
- The fundamentals. Second-quarter 2026 sales fell 14.3% to $8.529 million after sales to former top customer PendoTECH and a China distributor dropped to zero, and the company expects 2026 sales to decline 10% to 13%.
- Post-tender trading. Remaining shares lose the $75 bid after October 27, and a smaller float can trade less often.
What are the key facts to verify?
- The final terms and any further extension in the company's amended tender filing.
- How many shares are tendered and the proration factor once results are announced.
- Third-quarter 2026 sales, margins and cash on October 22, 2026.
- Whether directors and officers tender any of their own shares.
What would prove it right or wrong?
Signals the CEO's undervaluation view holds:
- UTMD trades at or above $75 after the tender closes.
- Quarterly sales stabilize and margins hold.
- Per-share earnings rise as the share count falls.
Signals it is failing:
- The stock slides well below $75 after October 27.
- Sales declines run past the guided 10% to 13% range.
- Heavy proration leaves tendering holders with most of their shares.
This is journalism and commentary, not investment advice. We hold no position unless stated.